Torin 1

For research use only. Not for use in humans.

Catalog No.S2827

99 publications

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Selleck's Torin 1 has been cited by 99 publications

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nat Metab, 2020, 2(1):41-49

PubMed: 31993556 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )
Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )

Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )
Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )
Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMECwN\|A3KM7:TR?=	MV3TRW5ITVJ?
OCUB-M	NGrUbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hu[WlEPTB;MD6wNFE6PCEQvF2=	MlTJV2FPT0WU
DOHH-2	M1fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HUemlEPTB;MD6wNFIzPSEQvF2=	NYmyepN{W0GQR1XS
NOS-1	NXnWTZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMECyOFIh\|ryP	MlTTV2FPT0WU
L-363	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMECyPFQh\|ryP	NESyUXBUSU6JRWK=
RL95-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2r1T2lEPTB;MD6wNFMzKM7:TR?=	MmHTV2FPT0WU
BL-70	M2LEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HjemlEPTB;MD6wNFM{PyEQvF2=	NWjPeW9KW0GQR1XS
TGBC1TKB	NIPDXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f2N2lEPTB;MD6wNFM4QSEQvF2=	MWfTRW5ITVJ?
697	NXLmR2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrxTWM2OD1yLkCwOlM1KM7:TR?=	MlfJV2FPT0WU
RPMI-8226	NYjRTodbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPZTWM2OD1yLkCwOlUyKM7:TR?=	MlLmV2FPT0WU
BL-41	NFvMdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rFS2lEPTB;MD6wNFY6PiEQvF2=	NXW4b4VtW0GQR1XS
MRK-nu-1	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTqXYdKSzVyPUCuNFA4ODdizszN	M{\TT3NCVkeHUh?=
EW-1	M3K4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlqyTWM2OD1yLkCwO\|Q6KM7:TR?=	Mn;JV2FPT0WU
EVSA-T	NEW2N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIi2fFdKSzVyPUCuNFA5QTJizszN	M1n0OXNCVkeHUh?=
HUTU-80	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17XSGlEPTB;MD6wNFkzQSEQvF2=	MXXTRW5ITVJ?
VA-ES-BJ	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;xRnpKSzVyPUCuNFA6QDRizszN	M4rySXNCVkeHUh?=
GCIY	NIH6PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37qeGlEPTB;MD6wNVAxPyEQvF2=	M4\RSXNCVkeHUh?=
ES6	M1;TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojDTWM2OD1yLkCxNFg{KM7:TR?=	MYrTRW5ITVJ?
NALM-6	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17TZ2lEPTB;MD6wNVExOiEQvF2=	NH\XNnBUSU6JRWK=
LB996-RCC	M17Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjQTWM2OD1yLkCxNVM4KM7:TR?=	MkXiV2FPT0WU
EW-16	NWXJWokyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L0RWlEPTB;MD6wNVE6OiEQvF2=	NIj3flNUSU6JRWK=
KALS-1	NYrDUIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\Mc3VZUUN3ME2wMlAyOTl6IN88US=>	MXzTRW5ITVJ?
OPM-2	M3\ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO3NplVUUN3ME2wMlAyOjlizszN	M{D0ZnNCVkeHUh?=
KU812	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqyTWM2OD1yLkCxNlk3KM7:TR?=	M2H4UHNCVkeHUh?=
A4-Fuk	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moq5TWM2OD1yLkCxN\|E6KM7:TR?=	NUnsSYdHW0GQR1XS
KGN	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;Nb2N7UUN3ME2wMlAyOzV7IN88US=>	MVnTRW5ITVJ?
KS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEGzPVIh\|ryP	NXS0NGZmW0GQR1XS
no-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Tpb2lEPTB;MD6wNVM6PSEQvF2=	NFHGdmxUSU6JRWK=
PSN1	M{DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMEG0NFkh\|ryP	MnvBV2FPT0WU
SK-LMS-1	M2[zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEG0NVMh\|ryP	MmDqV2FPT0WU
LS-411N	M2m0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMEG0N\|kh\|ryP	M{\0bnNCVkeHUh?=
HT-144	NGLTVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDONGtCUUN3ME2wMlAyPDVzIN88US=>	NXXodIpLW0GQR1XS
ACN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMEG1JO69VQ>?	MlzzV2FPT0WU
RKO	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLsTWM2OD1yLkCxOVM{KM7:TR?=	MXTTRW5ITVJ?
CMK	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjHTWM2OD1yLkCxOVQ{KM7:TR?=	M335TnNCVkeHUh?=
GB-1	NVH6NWY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrWZm5yUUN3ME2wMlAyPTV\|IN88US=>	MU\TRW5ITVJ?
KE-37	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPMTWM2OD1yLkCxOVc{KM7:TR?=	NUf0cY5sW0GQR1XS
no-10	M1nxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojITWM2OD1yLkCxOVg1KM7:TR?=	MYjTRW5ITVJ?
MOLT-16	M1j5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfTTWM2OD1yLkCxOlIzKM7:TR?=	M3K1T3NCVkeHUh?=
HEL	M1;1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\IN\|VOUUN3ME2wMlAyPjRizszN	MXzTRW5ITVJ?
NCI-H1355	NYjKVW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPoTWM2OD1yLkCxOlQ3KM7:TR?=	MX\TRW5ITVJ?
IST-MEL1	M2LyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMEG3O\|Qh\|ryP	MX7TRW5ITVJ?
MHH-PREB-1	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUntO\|VvUUN3ME2wMlAyQDF6IN88US=>	MlvEV2FPT0WU
ES8	NHiyfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMEG4OFQh\|ryP	Ml31V2FPT0WU
LC-2-ad	M1:wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMEKxN\|ch\|ryP	MXrTRW5ITVJ?
LAMA-84	NEPyZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzKcJFDUUN3ME2wMlAzOTZ5IN88US=>	MWTTRW5ITVJ?
BV-173	M13ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMEKyNFMh\|ryP	Mm\SV2FPT0WU
SW872	NXfjXYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vLXmlEPTB;MD6wNlI1PyEQvF2=	NVnKdGRoW0GQR1XS
SK-UT-1	NXXkfGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX6VZhKSzVyPUCuNFIzPjFizszN	Mkn2V2FPT0WU
OS-RC-2	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37BZWlEPTB;MD6wNlMzOyEQvF2=	NIXHTXRUSU6JRWK=
NCI-H747	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn5Z2J1UUN3ME2wMlAzOzNizszN	NULxdGc{W0GQR1XS
MZ2-MEL	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LxdGlEPTB;MD6wNlM{PyEQvF2=	M3zaeHNCVkeHUh?=
TE-11	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMEKzO\|Ih\|ryP	M{\PeXNCVkeHUh?=
KURAMOCHI	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LNZ2lEPTB;MD6wNlQyPCEQvF2=	MXjTRW5ITVJ?
HD-MY-Z	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEK0NlYh\|ryP	MXzTRW5ITVJ?
GI-1	Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMEK0Olkh\|ryP	MVjTRW5ITVJ?
LB1047-RCC	NHrmdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDWeJhKSzVyPUCuNFI1QDhizszN	M3LUb3NCVkeHUh?=
TE-12	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7uWnJsUUN3ME2wMlAzPTVizszN	NWHHOZdEW0GQR1XS
MZ7-mel	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PiZ2lEPTB;MD6wNlYxQSEQvF2=	NEH3e4RUSU6JRWK=
MMAC-SF	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILhfnhKSzVyPUCuNFI3OzNizszN	NVTBR2pFW0GQR1XS
A101D	NEPVTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEK2OUDPxE1?	MlvIV2FPT0WU
GR-ST	NV;5cXAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2juXWlEPTB;MD6wNlY2PSEQvF2=	NUTaWGVPW0GQR1XS
MC116	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLCUGVKSzVyPUCuNFI3QCEQvF2=	MnTOV2FPT0WU
Ramos-2G6-4C10	NE[yUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvIXYlOUUN3ME2wMlAzPzVizszN	M13rXnNCVkeHUh?=
ATN-1	NGHkW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LvTmlEPTB;MD6wNlc5QSEQvF2=	NUXUSYZtW0GQR1XS
MFH-ino	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1K3XGlEPTB;MD6wNlgyOiEQvF2=	MmPJV2FPT0WU
DEL	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEK4NVUh\|ryP	Mn7oV2FPT0WU
OCI-AML2	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[wVVBCUUN3ME2wMlAzQDdzIN88US=>	MkP1V2FPT0WU
LXF-289	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPqdFZKSzVyPUCuNFI5PzJizszN	NEHocWlUSU6JRWK=
IA-LM	M17H[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2yVZdKSzVyPUCuNFI6OTdizszN	MWHTRW5ITVJ?
EoL-1-cell	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHGydnhKSzVyPUCuNFI6QTZizszN	NYLyNm1PW0GQR1XS
OVCAR-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLkTWM2OD1yLkCzNFk1KM7:TR?=	NWn5RphEW0GQR1XS
ES1	M2\1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXJTWM2OD1yLkCzNFk4KM7:TR?=	MVTTRW5ITVJ?
CESS	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn0RpJKSzVyPUCuNFMxQTlizszN	MVzTRW5ITVJ?
GAK	NIrSfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3nTWM2OD1yLkCzNVg3KM7:TR?=	M{jHVnNCVkeHUh?=
NTERA-S-cl-D1	NH;SPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWridGxnUUN3ME2wMlA{OjJ4IN88US=>	M4DmZ3NCVkeHUh?=
TE-10	M4XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMEOzNVEh\|ryP	NIThZ\|lUSU6JRWK=
CCRF-CEM	MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fMc2lEPTB;MD6wN\|M4OSEQvF2=	M2TqcnNCVkeHUh?=
NMC-G1	NHHoSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEO0OFgh\|ryP	M4DNdHNCVkeHUh?=
HOP-62	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHjbXpKSzVyPUCuNFM2PTZizszN	NIW5eFVUSU6JRWK=
SH-4	NVr6fVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvrNmlKSzVyPUCuNFM2QDJizszN	MmXEV2FPT0WU
NCI-H1648	NHHnNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVW2XYFYUUN3ME2wMlA{PjJ{IN88US=>	M2LBbXNCVkeHUh?=
EB-3	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDjW\|dKSzVyPUCuNFM3PDNizszN	MYDTRW5ITVJ?
BB65-RCC	NEKxU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEO2PVEh\|ryP	MX;TRW5ITVJ?
BE-13	M{DXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknMTWM2OD1yLkCzO\|U6KM7:TR?=	Mlr6V2FPT0WU
CP67-MEL	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\OTIxKSzVyPUCuNFM4PTlizszN	MYTTRW5ITVJ?
SW954	NFuxVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljJTWM2OD1yLkCzO\|kh\|ryP	MXzTRW5ITVJ?
TE-5	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvJWYpKSzVyPUCuNFM5PTRizszN	NYe1W4xDW0GQR1XS
HCE-4	NYXWcIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\tNVVLUUN3ME2wMlA{QDV3IN88US=>	NXfJd5M4W0GQR1XS
LC-1F	NVHsUnd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnYUoRKSzVyPUCuNFM6QDlizszN	M3LhdnNCVkeHUh?=
TK10	MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjIZZhNUUN3ME2wMlA1ODF7IN88US=>	NYXwOG0xW0GQR1XS
SJSA-1	M4nUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjWW49KSzVyPUCuNFQyQDhizszN	MYTTRW5ITVJ?
Daudi	M3XOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXBTWM2OD1yLkC0NlI2KM7:TR?=	MXHTRW5ITVJ?
SW982	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvxTJp6UUN3ME2wMlA1OjR4IN88US=>	NGe1V\|FUSU6JRWK=
SF126	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEex[4lKSzVyPUCuNFQ{PjFizszN	MlLCV2FPT0WU
TE-15	M3v5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DkXGlEPTB;MD6wOFQ{PSEQvF2=	MlKxV2FPT0WU
COLO-684	M1rBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHDT482UUN3ME2wMlA1PTZzIN88US=>	M{DGT3NCVkeHUh?=
8-MG-BA	NE\4RlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXpS4VKSzVyPUCuNFQ3OjlizszN	NYDwbGhjW0GQR1XS
NB13	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXG[ZZpUUN3ME2wMlA1Pzd4IN88US=>	M{DXdHNCVkeHUh?=
HCC1599	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMES4O\|kh\|ryP	MVnTRW5ITVJ?
SK-PN-DW	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVy2[5ZyUUN3ME2wMlA1QTR7IN88US=>	M2nzfnNCVkeHUh?=
ALL-PO	NHrPbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrETWM2OD1yLkC0PVU3KM7:TR?=	NIXjc45USU6JRWK=
NB6	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn2R\|BKSzVyPUCuNFUzPzFizszN	NGGwdINUSU6JRWK=
IST-SL2	M3zqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj3R2NHUUN3ME2wMlA2OzZ{IN88US=>	MnzPV2FPT0WU
BB30-HNC	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[xZWlEPTB;MD6wOVc{KM7:TR?=	MUDTRW5ITVJ?
SW962	NXfMXZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMEW3OlMh\|ryP	M{X4O3NCVkeHUh?=
TGBC24TKB	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17KZWlEPTB;MD6wOVc6QSEQvF2=	MlPVV2FPT0WU
KINGS-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHHTWM2OD1yLkC1PFA{KM7:TR?=	NEf0UXhUSU6JRWK=
HC-1	NIL5XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TYTGlEPTB;MD6wOVgzPyEQvF2=	NXvRfIFkW0GQR1XS
RS4-11	M2e5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmxS2tKSzVyPUCuNFU6OzhizszN	NYr4fGhnW0GQR1XS
LS-123	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrqTWM2OD1yLkC1PVQzKM7:TR?=	MVTTRW5ITVJ?
A3-KAW	MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjneI5EUUN3ME2wMlA3OjJ3IN88US=>	NVm4VFJMW0GQR1XS
SNB75	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmG2TWM2OD1yLkC2N\|QyKM7:TR?=	NYrrVJRKW0GQR1XS
SR	NE\LUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jqNmlEPTB;MD6wOlM4PCEQvF2=	MX7TRW5ITVJ?
LOUCY	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;KTWlEPTB;MD6wOlM6PCEQvF2=	MmnOV2FPT0WU
K5	M1LGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrHSHY3UUN3ME2wMlA3PDB\|IN88US=>	MlXiV2FPT0WU
Becker	NFGyO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwME[0NkDPxE1?	MY\TRW5ITVJ?
CTV-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqzdmRNUUN3ME2wMlA3PTR6IN88US=>	NIPYNWhUSU6JRWK=
KLE	M2nw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vXdWlEPTB;MD6wOlU5PCEQvF2=	NVrJO\|NjW0GQR1XS
MZ1-PC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nE[2lEPTB;MD6wOlU6QCEQvF2=	Ml;3V2FPT0WU
MOLT-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17Lc2lEPTB;MD6wOlYxPSEQvF2=	NIGyd5NUSU6JRWK=
MLMA	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PIWWlEPTB;MD6wOlc5KM7:TR?=	M3y3OnNCVkeHUh?=
A388	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwME[4PVMh\|ryP	M2jKNHNCVkeHUh?=
MV-4-11	NWD0NYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwME[5PVUh\|ryP	NIq5eY9USU6JRWK=
DSH1	M3XFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLZTWM2OD1yLkC3NVc{KM7:TR?=	NXK5WGV1W0GQR1XS
MONO-MAC-6	NYrjW5NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMEeyNVIh\|ryP	M{j2e3NCVkeHUh?=
ARH-77	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEeyO\|gh\|ryP	NVWz[W56W0GQR1XS
LB771-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP2UFV1UUN3ME2wMlA4PTR7IN88US=>	MWDTRW5ITVJ?
PF-382	NGHI[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ztdmlEPTB;MD6wO\|U3QSEQvF2=	NG\XcJdUSU6JRWK=
KM12	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH0R\|NVUUN3ME2wMlA4PjRizszN	M2DE[3NCVkeHUh?=
HAL-01	M1\2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HjfmlEPTB;MD6wO\|Y2QCEQvF2=	Mn7MV2FPT0WU
RPMI-8402	NI\0fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEe3PFkh\|ryP	NIPIUYhUSU6JRWK=
OMC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHhTWM2OD1yLkC3PFA1KM7:TR?=	M1jGenNCVkeHUh?=
HT	M{m1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfBZ5F4UUN3ME2wMlA5KM7:TR?=	M4TQSnNCVkeHUh?=
QIMR-WIL	NHPPdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[yeVdsUUN3ME2wMlA5ODV3IN88US=>	MYDTRW5ITVJ?
KNS-42	M1\neWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDLU\|hKSzVyPUCuNFgzODNizszN	M4\ZUnNCVkeHUh?=
BC-3	M4HoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPDbIhKSzVyPUCuNFgzODRizszN	MUPTRW5ITVJ?
ES4	NY[0dXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMEiyPVYh\|ryP	M37k[3NCVkeHUh?=
NCI-H23	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnCTWM2OD1yLkC4OFQh\|ryP	NE\2SJlUSU6JRWK=
LB2518-MEL	NEP0[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\pRodKSzVyPUCuNFg3QTZizszN	NHn0fVhUSU6JRWK=
LC4-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTrWYdKSzVyPUCuNFg4OzhizszN	NXK1WVljW0GQR1XS
SIG-M5	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVX2[pNkUUN3ME2wMlA5QTB2IN88US=>	NFHKRnJUSU6JRWK=
LP-1	M2rKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fM[WlEPTB;MD6wPFk{QCEQvF2=	MmGxV2FPT0WU
TE-8	NWXacldxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnZdIRvUUN3ME2wMlA6ODF4IN88US=>	MmnQV2FPT0WU
K-562	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D0VWlEPTB;MD6wPVEzKM7:TR?=	NYLyTZd4W0GQR1XS
J-RT3-T3-5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\LS2lEPTB;MD6wPVE2OyEQvF2=	NGjVS5RUSU6JRWK=
DU-4475	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX[4dG9HUUN3ME2wMlA6OTZ3IN88US=>	NVnyXndKW0GQR1XS
RXF393	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vJOGlEPTB;MD6wPVQ3OiEQvF2=	NEPrSJFUSU6JRWK=
NB5	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\DUWlEPTB;MD6wPVYzPSEQvF2=	M{HxSXNCVkeHUh?=
A704	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K4TGlEPTB;MD6wPVc1OSEQvF2=	NXL0emVuW0GQR1XS
SF268	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHZO3ZKSzVyPUCuNFk5OjVizszN	MlOyV2FPT0WU
UACC-257	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTjV3hKSzVyPUCuNFk5OzNizszN	M17LbXNCVkeHUh?=
L-428	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\FbJRKSzVyPUCuNVA{OiEQvF2=	NHTDZ\|NUSU6JRWK=
ST486	NUXXTG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDZTWM2OD1yLkGwOlA3KM7:TR?=	M{TDR3NCVkeHUh?=
SK-MM-2	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMUC3NFkh\|ryP	NX32b4NkW0GQR1XS
COR-L279	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P0SmlEPTB;MD6xNFg{OiEQvF2=	NFf6bmVUSU6JRWK=
JiyoyeP-2003	NXHlZo44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrJRVZZUUN3ME2wMlExQDR\|IN88US=>	NFXKSoZUSU6JRWK=
GT3TKB	M{S5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:2OmlEPTB;MD6xNFkyQCEQvF2=	MnzzV2FPT0WU
HCE-T	NXf4c3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMUC5OEDPxE1?	NWLLZpExW0GQR1XS
SBC-1	M3;HVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED0fIhKSzVyPUCuNVEyOTlizszN	Mn3KV2FPT0WU
KNS-81-FD	MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfrTWlKSzVyPUCuNVEzPzNizszN	NHnOeGpUSU6JRWK=
NCI-H2126	NYrwc4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHrXVlVUUN3ME2wMlEyOzl2IN88US=>	NGD0ZmVUSU6JRWK=
EM-2	NGK1d3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[wdIJGUUN3ME2wMlEyPTJ7IN88US=>	M1HDNHNCVkeHUh?=
JAR	M3K1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PNNmlEPTB;MD6xNVU6QCEQvF2=	M1\UN3NCVkeHUh?=
NB17	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrOOWNKSzVyPUCuNVE3PTJizszN	NXfWepEzW0GQR1XS
LB647-SCLC	M3\LUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMUG3NFUh\|ryP	NEnucXVUSU6JRWK=
CAL-148	M{XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vBN2lEPTB;MD6xNVgh\|ryP	M4DjS3NCVkeHUh?=
K052	NF3lOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMUG4OVEh\|ryP	MVzTRW5ITVJ?
KARPAS-299	NYftZYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm5T\|dKSzVyPUCuNVIzOzNizszN	M1r6[3NCVkeHUh?=
KARPAS-422	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{O1[WlEPTB;MD6xNlQ{OiEQvF2=	NFPYVmRUSU6JRWK=
LOXIMVI	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMUK1NVUh\|ryP	MoXGV2FPT0WU
SCC-3	NH;k[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmKzTWM2OD1yLkGyPFUyKM7:TR?=	M4S5WHNCVkeHUh?=
LU-139	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMUK5O\|Uh\|ryP	MWPTRW5ITVJ?
COLO-320-HSR	NWXKdIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHOTWM2OD1yLkGzNFg3KM7:TR?=	M3X3S3NCVkeHUh?=
ONS-76	NVKw[ZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHKxSIpKSzVyPUCuNVMyOyEQvF2=	MYnTRW5ITVJ?
U-266	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLF[WxKSzVyPUCuNVMzPDVizszN	M2XSNnNCVkeHUh?=
HH	M2\6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfvS\|hoUUN3ME2wMlE{PTN3IN88US=>	NXXGWHJKW0GQR1XS
BB49-HNC	NUfjc21bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fkRmlEPTB;MD6xN\|U5PyEQvF2=	NUTvTZJ{W0GQR1XS
NCI-SNU-5	NWjoN2U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ewVGlEPTB;MD6xN\|U6PiEQvF2=	NUe1dZA6W0GQR1XS
C2BBe1	M3\4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkftTWM2OD1yLkGzO\|Q3KM7:TR?=	NX7H[lNvW0GQR1XS
ML-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoO2TWM2OD1yLkGzPVU{KM7:TR?=	NUn4eWZnW0GQR1XS
SCH	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1OwVmlEPTB;MD6xN\|k4PCEQvF2=	M3;KVHNCVkeHUh?=
NCI-H82	NF\PVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\mSGlEPTB;MD6xOFExPCEQvF2=	NX7rNolCW0GQR1XS
MDA-MB-134-VI	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH6Vnl2UUN3ME2wMlE1OjV{IN88US=>	MXLTRW5ITVJ?
SK-N-DZ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\RTVhKSzVyPUCuNVQ4OTlizszN	MnHyV2FPT0WU
HL-60	M{[3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMUS5NkDPxE1?	NFrue2NUSU6JRWK=
LB373-MEL-D	NF7MN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMUW1N\|kh\|ryP	M3rOSXNCVkeHUh?=
LB831-BLC	M{\SNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMU[wO\|Yh\|ryP	NYHLeZE{W0GQR1XS
SK-NEP-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnrc5RGUUN3ME2wMlE3OTBzIN88US=>	NV\uOmNYW0GQR1XS
IMR-5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\4b2lEPTB;MD6xOlQ5OyEQvF2=	NF7Ce2JUSU6JRWK=
Calu-6	M{LaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMU[1N\|ch\|ryP	NVTWWHlSW0GQR1XS
NCI-H1882	M2DnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnvbmNKSzVyPUCuNVY4OjhizszN	NUO5NlY5W0GQR1XS
NCI-H446	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjzNmI2UUN3ME2wMlE3QDlzIN88US=>	NXvwSGtsW0GQR1XS
GI-ME-N	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3juOmlEPTB;MD6xPFAzKM7:TR?=	MWjTRW5ITVJ?
MPP-89	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPWWXNKSzVyPUCuNVgyOjFizszN	NWK2b2YxW0GQR1XS
CGTH-W-1	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUi0N\|Yh\|ryP	M1LFVXNCVkeHUh?=
MEG-01	NWfTR3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPOVo9[UUN3ME2wMlE5PjJ6IN88US=>	NVvaXI9KW0GQR1XS
NCI-H748	NFS3OJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPQTWM2OD1yLkG4PVEyKM7:TR?=	NITKeJBUSU6JRWK=
COLO-829	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\F[pFEUUN3ME2wMlIxPjd\|IN88US=>	NWXBW2tYW0GQR1XS
GOTO	NUDuW3hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITvWmlKSzVyPUCuNlA4OyEQvF2=	MYrTRW5ITVJ?
EW-3	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3O2RWlEPTB;MD6yNVcyQCEQvF2=	MVHTRW5ITVJ?
KY821	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnj0TWM2OD1yLkKyNFQ2KM7:TR?=	M3nlSXNCVkeHUh?=
CTB-1	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn6OFhsUUN3ME2wMlIzOjJ6IN88US=>	MoWxV2FPT0WU
TALL-1	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHteXB6UUN3ME2wMlIzQTJzIN88US=>	NWHtXVhCW0GQR1XS
NCI-H209	M1;0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTCeXNXUUN3ME2wMlIzQTZ{IN88US=>	M4PqN3NCVkeHUh?=
IST-MES1	NHGwPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjvT\|JKSzVyPUCuNlM2OSEQvF2=	Mk\lV2FPT0WU
DMS-114	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnpRnU5UUN3ME2wMlI{QTl\|IN88US=>	NUnXbVU1W0GQR1XS
SNU-C2B	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\iVWlEPTB;MD6yOFMyPiEQvF2=	NG[wcGhUSU6JRWK=
DG-75	NU\ZVVc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTvPYZKSzVyPUCuNlYyQTVizszN	MmDuV2FPT0WU
D-336MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHruNXlKSzVyPUCuNlY2PTdizszN	MojIV2FPT0WU
KMOE-2	M1zHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILYXFdKSzVyPUCuNlc2OzhizszN	NYDEZ2VbW0GQR1XS
NB1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[0TWM2OD1yLkK3PVI3KM7:TR?=	NWW3fYNZW0GQR1XS
RH-1	M{OzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLGTWM2OD1yLkK3PVg6KM7:TR?=	NEOyUG1USU6JRWK=
TE-1	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33aO2lEPTB;MD6yPFQ4QSEQvF2=	MmHaV2FPT0WU
RPMI-6666	NFO4NHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DySWlEPTB;MD6yPFg1KM7:TR?=	M4Dw[HNCVkeHUh?=
TE-9	M3rWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV30O2o5UUN3ME2wMlI5QTh3IN88US=>	NELvSY5USU6JRWK=
BT-474	M4jGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDVTWM2OD1yLkK5N\|M1KM7:TR?=	NV\vZodyW0GQR1XS
COLO-668	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW0XZJ3UUN3ME2wMlI6PDJ7IN88US=>	MYXTRW5ITVJ?
NCI-H1581	NG\PdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;vZmlEPTB;MD6yPVY5QSEQvF2=	Ml64V2FPT0WU
MN-60	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7PVpJiUUN3ME2wMlI6QTB3IN88US=>	NEPGN\|hUSU6JRWK=
L-540	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TVN2lEPTB;MD6zNFA5OSEQvF2=	MofDV2FPT0WU
MOLT-13	M4nQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPZbFdKSzVyPUCuN\|AyQDNizszN	NXX2NIF4W0GQR1XS
NCI-SNU-16	NX\SfW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHmZZdxUUN3ME2wMlMxOjB3IN88US=>	NXqwfnp1W0GQR1XS
NCI-H64	M4X1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XVdmlEPTB;MD6zNFM{OSEQvF2=	MX7TRW5ITVJ?
CP66-MEL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS1Z3p7UUN3ME2wMlMyPDF3IN88US=>	M{[3N3NCVkeHUh?=
NB69	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXn[GVKSzVyPUCuN\|IyQDhizszN	M1\OfHNCVkeHUh?=
NCI-H2196	NGHVSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HDVGlEPTB;MD6zN\|A{PiEQvF2=	NXrSfG9GW0GQR1XS
MHH-CALL-2	Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrIW5VnUUN3ME2wMlM{PDZ6IN88US=>	M2L2RnNCVkeHUh?=
HCC2157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\uTWM2OD1yLkOzPVU1KM7:TR?=	MlSxV2FPT0WU
LS-1034	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGm0NphKSzVyPUCuN\|Y{QDhizszN	MX\TRW5ITVJ?
BOKU	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\6V2lEPTB;MD6zO\|E6QSEQvF2=	M3O4dnNCVkeHUh?=
GDM-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwM{eyN\|Qh\|ryP	M3nOd3NCVkeHUh?=
TGW	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnLcYlHUUN3ME2wMlM4PDV\|IN88US=>	M1GxZXNCVkeHUh?=
SNU-C1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwM{iyNVUh\|ryP	MWrTRW5ITVJ?
LS-513	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\QWmlEPTB;MD6zPVA4OSEQvF2=	NUTvNW5jW0GQR1XS
NOMO-1	M4Dx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwM{m5O\|Eh\|ryP	NUHEbGNnW0GQR1XS
MS-1	M{HHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljzTWM2OD1yLkSwNVc4KM7:TR?=	MYrTRW5ITVJ?
EKVX	NVPV[I5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwNES0OlEh\|ryP	NWraeY5bW0GQR1XS
SK-MEL-2	NXrGVVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrxWWF1UUN3ME2wMlQ3PCEQvF2=	NEfTbFNUSU6JRWK=
HCC1187	M1u5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwNE[3Olgh\|ryP	NWXvWYtXW0GQR1XS
HCC2218	NHHnN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7UbHFJUUN3ME2wMlQ4OjJ5IN88US=>	M4rRNXNCVkeHUh?=
NCI-H187	M2PHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrz[ldKSzVyPUCuOFc5PCEQvF2=	M3XOdnNCVkeHUh?=
DB	NYTudVduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLtTWM2OD1yLkWwNFU2KM7:TR?=	Mn\UV2FPT0WU
NCI-H69	NEHmSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PXcmlEPTB;MD61NFI1PyEQvF2=	NVrhNnlSW0GQR1XS
NCI-H1694	M1X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W2O2lEPTB;MD61NFY6PyEQvF2=	M1LtcXNCVkeHUh?=
CA46	M2Pibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe5RZhXUUN3ME2wMlUxQTF5IN88US=>	NVLtVnZJW0GQR1XS
EHEB	M4TV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNUGxPVMh\|ryP	MlPtV2FPT0WU
NCCIT	NWq0V4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGW3ZmJKSzVyPUCuOVQ{OjFizszN	NYnLWWVqW0GQR1XS
NCI-H720	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNUS5OlIh\|ryP	M{[xXXNCVkeHUh?=
LU-134-A	NHznUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvN[IFKSzVyPUCuOVUzQTZizszN	NGf3dW5USU6JRWK=
MC-CAR	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17zd2lEPTB;MD61OVQ{OSEQvF2=	MUXTRW5ITVJ?
NEC8	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfVSGpKSzVyPUCuOVYyPzJizszN	M370RnNCVkeHUh?=
NCI-H524	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDPbmpKSzVyPUCuOVg4PDhizszN	MV3TRW5ITVJ?
NCI-H1963	NUSyUHNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DDSmlEPTB;MD62NlU5KM7:TR?=	NVT4W2lJW0GQR1XS
SU-DHL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNkS1NlYh\|ryP	MVzTRW5ITVJ?
NCI-H1522	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofhTWM2OD1yLk[0PFg{KM7:TR?=	NUDHOYEyW0GQR1XS
NCI-H1155	NW\yPHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rHRmlEPTB;MD62OVM2KM7:TR?=	MmrLV2FPT0WU
D-263MG	M3;wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT4coZUUUN3ME2wMlY3OTBzIN88US=>	M2q3c3NCVkeHUh?=
TE-6	NICyUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3GSYlKSzVyPUCuOlgyODRizszN	NYnyRWlWW0GQR1XS
NCI-H1417	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPzTWM2OD1yLk[5O\|EyKM7:TR?=	NX3xO4ZuW0GQR1XS
NCI-H510A	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1m5WGlEPTB;MD63O\|I{PiEQvF2=	NUPjeW5{W0GQR1XS
KARPAS-45	NWPTOoFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLNTXZuUUN3ME2wMlc5OjN3IN88US=>	NEXNNVBUSU6JRWK=
IST-SL1	M{nvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITKXohKSzVyPUCuPFU5OjVizszN	Mor6V2FPT0WU
COLO-824	NFSxZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO4WlVKSzVyPUCuPFc5OzVizszN	MUHTRW5ITVJ?
NCI-H526	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HwfWlEPTB;MD65NFk2QCEQvF2=	NGnRc4xUSU6JRWK=
NCI-H719	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jSemlEPTB;MD65OlY2PyEQvF2=	NWjPT5hUW0GQR1XS
SF539	M2T4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f4SWlEPTB;MD65PFM6PiEQvF2=	M{n2eHNCVkeHUh?=
NKM-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HSSGlEPTB;MD65PFY3OyEQvF2=	MXTTRW5ITVJ?
A253	NVTQSmJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XhRmlEPTB;MD65PFg5PSEQvF2=	MlzZV2FPT0WU
TE-441-T	NXHsUoNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPtUFlKSzVyPUGuNFQ{PSEQvF2=	MUHTRW5ITVJ?
COR-L88	M1zDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm2UlhKSzVyPUGuNVE{PTRizszN	M2G1RnNCVkeHUh?=
CPC-N	M3nMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf0TJRTUUN3ME2xMlE2QDh6IN88US=>	M2PXTXNCVkeHUh?=
NCI-H2107	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvrTWM2OD1zLkG3NlYyKM7:TR?=	MWnTRW5ITVJ?
ECC4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFwMUi2PVMh\|ryP	M4XUe3NCVkeHUh?=
NCI-H2141	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmniTWM2OD1zLkG5Nlk6KM7:TR?=	MVfTRW5ITVJ?
NCI-H1770	NIXITHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFwM{K5Nlgh\|ryP	NInuU25USU6JRWK=
NCI-SNU-1	NVfmPZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHFTWM2OD1zLkOzNFQh\|ryP	M2nOSHNCVkeHUh?=
LU-165	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TFbmlEPTB;MT60OVQ3PyEQvF2=	NHW0ToNUSU6JRWK=
Raji	NX\Qc2M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTFwNEeyOVkh\|ryP	NI\2Z\|lUSU6JRWK=
EW-24	M4CxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe1Z5R1UUN3ME2xMlU1PjF7IN88US=>	NVj6ZnhqW0GQR1XS
KP-N-RT-BM-1	M1[1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYm1S4lSUUN3ME2xMlU3PTVzIN88US=>	MWPTRW5ITVJ?
SK-MEL-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXz[lBpUUN3ME2xMlY1QDd5IN88US=>	NYDreYhyW0GQR1XS
SCLC-21H	M4LncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwNk[2OVEh\|ryP	NEfZRo1USU6JRWK=
SIMA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mom1TWM2OD1zLk[4NlM{KM7:TR?=	NHHHd3FUSU6JRWK=
NCI-H1304	NYnaXYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nQR2lEPTB;MT63NFc3PSEQvF2=	Ml3RV2FPT0WU
REH	NXvCc5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[4TWM2OD1zLkexNFc5KM7:TR?=	NEPzT2dUSU6JRWK=
KP-N-YS	NILieIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml30TWM2OD1zLkmzOVUyKM7:TR?=	NXy4[IkzW0GQR1XS
DMS-153	NGDmUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7qTY9KSzVyPUGuPVc2QSEQvF2=	NEnGcXNUSU6JRWK=
NB10	M2LLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTMdI15UUN3ME2yMlIxQDd6IN88US=>	NWrZTWw2W0GQR1XS
NCI-H345	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSwTWM2OD1{Lk[xPVA2KM7:TR?=	MljoV2FPT0WU
SK-N-FI	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjuWoVKSzVyPUKuO\|U{QDFizszN	MXnTRW5ITVJ?
NCI-H1092	NETMV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT3bYZ3UUN3ME2yMlk2Ozl2IN88US=>	NV64ZXZIW0GQR1XS
KM-H2	M3XRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzKO48{UUN3ME2zMlY2Ozl4IN88US=>	Ml3TV2FPT0WU
KG-1	NV\pV4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn1TWM2OD1\|LkexOlg5KM7:TR?=	Ml\0V2FPT0WU
D-283MED	NUjFN4dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTNwN{W4O{DPxE1?	NIjUbIdUSU6JRWK=
LU-65	NYezb3JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPtSFRKSzVyPUSuNVE1QDVizszN	NYLCXnd6W0GQR1XS
MSTO-211H	NXPsXmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTRwMUi4PVgh\|ryP	M3\ObXNCVkeHUh?=
NCI-H2081	NVL0[JhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3QcnpqUUN3ME20MlI6OTd2IN88US=>	NUjLVpF4W0GQR1XS
D-247MG	NFLWV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;ocJFWUUN3ME20MlQ{OTlzIN88US=>	MkDEV2FPT0WU
P31-FUJ	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PFOGlEPTB;ND60OVAyQSEQvF2=	NF;kcXRUSU6JRWK=
DMS-79	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLI[HRKSzVyPUSuPVMyQDNizszN	M{HhW3NCVkeHUh?=
KASUMI-1	NIjqeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLuTWM2OD12Lkm3OVA6KM7:TR?=	MV3TRW5ITVJ?
JVM-3	M3:5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTVwMkWwNVQh\|ryP	MojKV2FPT0WU
LAN-6	NIPrRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFm0cnhKSzVyPUWuOVE4OzZizszN	NE\0eIhUSU6JRWK=
DJM-1	M2W4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPHe3BCUUN3ME21MlU3ODJ7IN88US=>	MWnTRW5ITVJ?
JVM-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTVwNkewPVIh\|ryP	MWHTRW5ITVJ?
U-87-MG	NWG3dYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q2WmlEPTB;NT64PVk3PCEQvF2=	M3[3NHNCVkeHUh?=
SHP-77	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3ocYxKSzVyPUWuPVQ6OjhizszN	NEDncIVUSU6JRWK=
RPMI-8866	M2\tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3OTodKSzVyPU[uNlcxOTNizszN	NX7afop7W0GQR1XS
ES7	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC0TWM2OD14LkO5PVI1KM7:TR?=	M4fieHNCVkeHUh?=
WSU-NHL	Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTZwNUG2NFkh\|ryP	NXPCcHI5W0GQR1XS
CAS-1	NH3KeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rwWGlEPTB;Nz6wPVc1QSEQvF2=	M1rzTHNCVkeHUh?=
MHH-NB-11	NX33e3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HTdmlEPTB;OD6yN\|E2OiEQvF2=	MXvTRW5ITVJ?
ES5	M3\uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTlwNUKyPFYh\|ryP	Mk\CV2FPT0WU
HDLM-2	NGrGXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLUdppKSzVyPUmuPVU6ODJizszN	NXrONVN6W0GQR1XS
NCI-H2171	M1v6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFyLkW5Nlch\|ryP	MkPhV2FPT0WU
LNCaP-Clone-FGC	NW\IR493T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFzLkO3NVgh\|ryP	NGrGN4VUSU6JRWK=
NCI-H1395	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfMWW9KSzVyPUGyMlI3QTlizszN	MnfMV2FPT0WU
NCI-H1436	NE\BZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTYXYF1UUN3ME2xN{4{OTl3IN88US=>	NYTlO5E1W0GQR1XS
RCC10RGB	M3HZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF\|LkOyNlEh\|ryP	NH\2[IJUSU6JRWK=
SW684	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[wfYVKSzVyPUGzMlk4QTdizszN	NWfleFM3W0GQR1XS
NCI-H1650	M2XIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV31S\|hnUUN3ME2xOU4xPDR5IN88US=>	MonJV2FPT0WU
EW-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjDcohHUUN3ME2xOU4zODJzIN88US=>	MX3TRW5ITVJ?
EC-GI-10	M4P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTF3Lki2OFQh\|ryP	MVjTRW5ITVJ?
CHP-126	M{\QSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rzfGlEPTB;MUeuNVkyQCEQvF2=	M4T3W3NCVkeHUh?=
NCI-H226	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7UTWM2OD1zOD6wOFA{KM7:TR?=	MWLTRW5ITVJ?
NCI-H1838	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnuRnp{UUN3ME2yNE4yQDR6IN88US=>	NVr2dZVOW0GQR1XS
EW-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHWzSnNKSzVyPUK0MlI4OThizszN	MWLTRW5ITVJ?
EB2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHpTWM2OD1\|MT61N\|E5KM7:TR?=	MU\TRW5ITVJ?
D-502MG	M3;2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLpTWM2OD12Mz65NlI6KM7:TR?=	MUjTRW5ITVJ?
U-698-M	M3HsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7ISZNKSzVyPUS4Mlg3PzFizszN	NHGzXpFUSU6JRWK=
ES3	NFfoSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzDNWF{UUN3ME20PU4{QDl\|IN88US=>	NWToOJZQW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CCC(=O)N1CCN(CC1)C2=CC=C(C=C2C(F)(F)F)N3C(=O)C=CC4=C3C5=CC(=CC=C5N=C4)C6=CC7=CC=CC=C7N=C6

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1